전위도의 동시 녹화 및 마취 된 흰쥐의 비주얼 사건 관련 전위

Executive Industry Relevance

Simultaneous ERG and VEP recording enables comprehensive assessment of retinal-to-cortical visual pathway integrity in preclinical models. This dual-modality approach supports mechanistic de-risking by linking retinal dysfunction to upstream cortical effects, informing target validation in neurodegenerative and ophthalmic disease research. The method enhances predictive confidence in early discovery by providing quantitative, translatable electrophysiological readouts.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Interrogates therapeutic hypotheses by correlating retinal electrophysiological changes with cortical visual processing deficits.
• Operational Value: Enables functional target validation through simultaneous measurement of retinal and visual pathway responses to light stimulation.
• Predictive Value: Supports portfolio triage by identifying compounds that modulate specific visual pathway components (e.g., rod bipolar, retinal ganglion cell function).

Screening & Assay Development

• Scientific Value: Prepares validated biological systems for downstream screening by establishing baseline retinal and cortical electrophysiological profiles.
• Operational Value: Delivers standardized, reproducible quantitative outputs (e.g., P2 amplitude, pSTR peak) for reliable compound screening.
• Scalability: Facilitates platform reuse across disease models due to consistent electrode preparation and signal acquisition protocols.

Translational & Preclinical Research

• Scientific Value: Maintains translational continuity by assessing disease-relevant visual pathway alterations from retina to cortex.
• Operational Value: Supports risk-adjusted advancement decisions through amplitude and timing analysis of ERG and VEP waveforms.
• Mechanistic De-risking: Clarifies whether retinal changes drive cortical dysfunction or occur independently, reducing false positives in target engagement.

Pipeline & Workflow Integration

The method integrates into the discovery continuum from target validation through lead identification to preclinical efficacy testing, providing electrophysiological biomarkers of visual pathway integrity.

• Discovery Biology: Supports hypothesis testing by measuring how genetic or pharmacological manipulations affect retinal neuronal and glial cell class responses.
• Screening: Enables assay readiness via stable, low-noise signal acquisition after electrode chloridation and proper dark adaptation.
• Analytics: Provides quantitative dependent variable measurements (ERG A/B waves, VEP peak-to-peak amplitude) for comparing experimental conditions.
• Translational Research: Connects to preclinical validation by modeling retinal ganglion and cone bipolar cell function using established intensity-response paradigms.
• Enterprise Reuse: Represents a reusable capability for chronic studies due to stable electrode implantation and standardized recording parameters.

Operational & Enterprise Impact

• Scientific Value: Reduces mechanistic ambiguity by distinguishing retinal versus cortical contributions to visual deficits.
• Operational Value: Ensures standardization through detailed electrode preparation (silver wire chloridation, loop sizing) and placement protocols.
• Strategic Value: Improves go/no-go decisions by linking target modulation to functional visual pathway outcomes.
• Portfolio Impact: Enables risk-adjusted prioritization based on dose-responsive changes in scotopic threshold responses and VEP amplitude.

Implementation Considerations

• Requires expertise in electrophysiology, microsurgery, and electrode fabrication for stable signal acquisition.
• Depends on instrumentation including Ganzfeld stimulator, Faraday cage, micro-manipulator, and differential amplifiers.
• Necessitates cross-team standardization of dark adaptation protocols and stimulus intensity ranges for reproducible data.
• Involves adaptation considerations across rodent strains and anesthesia regimens affecting pupil dilation and corneal sensitivity.
• Practical limitations include signal variability from improper electrode sizing or inadequate chloridation, as noted in the protocol.

Biopharma FAQs